Close

Anti-EBNA3A T cell receptor (CF3), pCDTCR1 (TCR-C051Z)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-EBNA3A T cell receptor (TCR) is constructed for the engineering of T cell to target EBV EBNA3A. The T cells are genetically modified through transduction with a lentiviral vector expressing EBNA3A-specific T cell receptor. And the vector product was designed for the treatment of EBV infection.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • EBNA3A
  • Target Species
  • EBV
  • Epitope
  • FLRGRAYGL
  • Format
  • Single-chain
  • Allele
  • HLA-B*0802
  • Targeting Diseases
  • EBV infection
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • TCR Clone
  • CF3
  • Host Species
  • Human

Target

  • Official Symbol
  • EBNA3A
  • Introduction
  • Epstein-Barr virus (EBV), a human gammaherpesvirus, can cause lymphocyte-proliferative diseases in immune-deficient people and is also etiologically associated with Burkitt's lymphoma, Hodgkin's disease, other B- and T-cell lymphomas, anaplastic nasopharyngeal carcinoma, and a small fraction of gastric carcinomas. Epstein-Barr Virus Nuclear Protein EBNA3A Is Critical for Maintaining Lymphoblastoid Cell Line Growth.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-EBNA3A T cell receptor (CF3), pCDTCR1 (TCR-C051Z). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.